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Abstract  
All-oral direct-acting antiviral (DAA) HCV therapies with cure responses of >90% is a major 
clinical advancement. However, the high DAA list price has led many governments to restrict 
their reimbursement. Study aims were to review the availability of, and national criteria for, 
interferon-free DAA therapy reimbursement among EU/EEA countries and Switzerland. 
Reimbursement documentation was reviewed from November 18, 2016 to August 1, 2017. 
Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-
infection restrictions. Among European countries/jurisdictions (n=35), the most commonly 
reimbursed DAA was ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin (94%, n=33), 
nearly half of countries/jurisdictions (49%, n=17) required ≥F2, 83% (n=29) had no listed 
drug or alcohol use restrictions, 94% (n=33) required a specialist prescriber, and 97% (n=34) 
had no additional restrictions for HIV-HCV co-infected persons. Findings have implications 
for meeting WHO targets with evidence of some countries not following the 2016 EASL 
HCV treatment guidelines. Funding: The Kirby Institute is funded by the Australian 
Government Department of Health. The views expressed in this publication do not 
necessarily represent the position of the Australian Government. 
 
Key words: hepatitis C virus, hepatitis C treatment, direct-acting antiviral, treatment 
restrictions, reimbursement, Europe, liver fibrosis, alcohol use, PWID, HIV-HCV co-
infection  
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INTRODUCTION 
Over 71 million (63 – 79) people are infected with chronic hepatitis C virus (HCV) infection 
globally with ~704,000 (652,100 – 769,600) HCV-related deaths each year.1-3 Compared to 
peginterferon-based therapies, simple, tolerable, all-oral HCV direct-acting antiviral (DAA) 
therapies achieve viral cure in >90% of patients, resulting in one of the greatest clinical 
advances in recent decades.4 Broad uptake of DAA therapies has the potential to substantially 
reduce the global HCV disease burden, in particular, HCV-related mortality and morbidity.5-7 
However, the high list price of DAA therapies in some countries has led national 
governments8, 9 to restrict patient reimbursement based on liver fibrosis severity, drug and 
alcohol use, and prescriber type.  
 
A 2014 study of Medicaid reimbursement criteria for sofosbuvir in the United States (US) 
showed some variability by state jurisdiction.8 The majority of states (88%) had drug and/or 
alcohol use restrictions, most (74%) required evidence of advanced fibrosis (≥F3), over-half 
(66%) had prescriber limitations, and one-quarter (25%) required HIV-HCV co-infected 
persons to demonstrate suppressed HIV RNA levels or be recipients of antiretroviral therapy.8 
An updated reimbursement study by Ooka et al. (2017) demonstrated that, overall, restrictions 
had lessened over a two year period (2014 - 2016).10 For example, 22 states required evidence 
of ≥F3 in 2016 as opposed to 31 states in 2014. This updated study highlights that several 
criteria continue to be incongruent with clinical recommendations which state that all persons 
willing to be treated (and who have no treatment contraindications) should be considered for 
HCV therapy.11-13    
 
In Europe, ~3.2 million (2.1 – 3.8) persons are estimated to have chronic HCV infection.14 
The primary HCV transmission route in the majority of European countries is injection drug 
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use.15-17 Although HCV incidence is decreasing overall in Europe, rates of liver-related 
deaths, decompensated cirrhosis, and hepatocellular carcinoma are all projected to increase 
20-30% by 2030 if broad access to DAA therapy is not achieved.14 This, in the context of 
2030 HCV global targets set by the World Health Organization (WHO) which  propose: a 
80% reduction in HCV incidence, 90% of persons with HCV diagnosed, 80% of persons with 
HCV treated, and a 65% reduction in HCV-related mortality.18 To meet WHO targets, it will 
be critical that countries incorporate strategies that optimise uptake of DAA therapy, 
including minimising DAA reimbursement restrictions.   
 
The aims of the study were to review the availability of interferon-free DAA therapy among 
European Union and European Economic Area (EU/EEA) countries and Switzerland; and to 
review national criteria for DAA therapy reimbursement among EU/EEA countries and 
Switzerland. 
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METHODOLOGY 
Data collection 
This study reviewed the availability of reimbursed DAA therapy and national criteria for 
DAA therapy reimbursement criteria among EU/EEA countries (including England, Northern 
Ireland, Scotland and Wales as separate jurisdictions) and Switzerland. Reimbursement 
criteria were reviewed for the following DAA regimens: sofosbuvir + ribavirin, 
sofosbuvir/ledipasvir + ribavirin, sofosbuvir/velpatasvir + ribavirin, 
ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin, elbasvir-grazoprevir + ribavirin, and 
sofosbuvir + daclatasvir + ribavirin.   
 
From November 18, 2016 to August 1, 2017, most data were extracted from publicly available 
documentation from government websites and online drug formularies with the assistance of 
study authors [see appendix p.1]. Supporting documentation, e.g. national HCV guidelines, 
was also collected when available [see appendix p.3]. If challenges arose in recovering 
information, one of three study authors contacted the study author from the country of interest 
to enable access. Given that most documentation was in a language other than English, study 
authors were fundamental to identifying documents of relevance. Independent document 
searches were conducted by three study authors to further corroborate search findings. Study 
authors of each country were also contacted to provide clarification if there were 
inconsistencies between documents and/or additional documentation was needed. In the event 
that documentation for a country could not be located, this finding was categorised as ‘Not 
available’.  
 
Information was reviewed to determine the availability of reimbursed HCV DAAs in Europe 
(categories were: Yes; No). In the event that an individual could retrieve access to a specific 
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therapy (e.g. sofosbuvir + daclatasvir + ribavirin) but this therapy was not reimbursed, this 
was categorised as ‘No’. Based on prior HCV DAA reimbursement studies,8, 9 primary 
outcomes were criteria restrictions based on: 1) minimum fibrosis stage [METAVIR or 
equivalent; Meta-Analysis of Histologic Data in Viral Hepatitis]; 2) drug and/or alcohol use; 
3) prescriber type; and 4) HIV co-infection. If information for a specific outcome was not 
reported with the remaining outcomes, this outcome was categorised as ‘None listed’. 
Regarding primary outcomes, fibrosis stage was categorised as: No restriction; F2; F3, F4; 
Other; None listed; Not available. Fibrosis stage could be assessed through liver biopsy, 
transient elastography, biomedical markers, or a combination. It was anticipated that in many 
countries, patients with extrahepatic manifestations (e.g. cryoglobulinemia) would have had 
different criteria than asymptomatic patients (e.g. different fibrosis stage restrictions). Given 
that the primary interest of this study was to assess criteria experienced by the majority of 
patients, the minimum fibrosis stage for asymptomatic patients was recorded. Drug or alcohol 
use was categorised as: Prioritised; No restrictions; Additional restrictions; None listed; Not 
available. ‘Prioritised’ meant that persons with drug or alcohol use dependencies had fewer 
restrictions for DAA therapy access than persons without drug or alcohol use dependencies.  
‘No restrictions’ meant that persons with drug or alcohol use dependencies could receive 
reimbursed DAA therapies. For instance, a person who engaged in active injection drug use 
(or a history of injection use) could be offered DAA therapy. ‘Additional restrictions’ meant 
that persons with drug or alcohol use dependencies needed to fulfil further criteria prior to 
being eligible for DAA therapy. Based on prior evidence,8, 10 study authors anticipated that 
one example of a drug or alcohol use restriction that may be in existence in European 
countries would be a mandatory period of abstinence from substance use prior to therapy (e.g. 
6 month period of abstinence from drug use). In addition to this restriction, study authors 
made note of any other drug or alcohol use restriction that was listed in reimbursement 
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criteria. Prescriber type categories were: No restriction; Specialist only; None listed; Not 
available. ‘No restriction’ meant that a healthcare practitioner other than a specialist (e.g. 
general practitioner) could prescribe interferon-free HCV DAA therapies. ‘Specialist only’ 
meant that there was a requirement that the prescriber worked within a specialised field. 
Options included, but were not limited to, hepatologist, infectious disease specialist, internal 
medicine specialist, and gastroenterologist. If a country permitted a general practitioner to 
prescribe HCV DAAs but these therapies were not reimbursed, then this was categorised as a 
restriction (i.e. Specialist only) because we were specifically interested in access to 
reimbursed therapies. Moreover, the study focus was specific to prescribing; whether a 
general practitioner or nurse practitioner could treat and monitor a patient who received 
interferon-free HCV DAA therapy was not recorded. Lastly, HIV co-infection categories 
were: Prioritised; Eligible; None listed; Not available. ‘Prioritised’ meant that persons with 
HIV-HCV co-infection were given treatment precedence over persons with HCV mono-
infection (i.e. had fewer reimbursement restrictions). ‘Eligible’ meant that persons with HIV 
co-infection had the same restriction criteria as persons with HCV mono-infection. ‘Other’ 
was also a possible category for any of the primary outcomes, when appropriate.    
 
Data were organized with descriptive statistics with Microsoft Excel® (version 2010, 
Redmond, USA). With separate Excel spreadsheets, two study authors categorised the 
outcome criteria of ~15 European countries/jurisdictions each. Once completed, the same two 
study authors independently cross-checked each other’s categorisation against the 
documentation. Study authors were then contacted by these two study authors when further 
clarification was required to resolve any inconsistencies. Following this stage, information 
was updated as appropriate. Map imagery was created with Tableau Software (version 10.2.2, 
Seattle, USA).  
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Role of the funding source 
The funding source did not have any input into the study design, data collection, data 
analysis, interpretation of the data, writing of the report, or the decision to submit the 
manuscript for publication. The corresponding author had full access to all the data in this 
study and had final responsibility for the decision to submit the publication. 
 
 
 12 
 
FINDINGS 
All European countries/jurisdictions (100%, n=35) provided reimbursement for DAAs to treat 
HCV infection. As of August 1, 2017, the most commonly reimbursed therapy was 
ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin (94%, n=33). Sofosbuvir + 
daclatasvir + ribavirin (63%, n=22) was the least likely to be reimbursed. Most countries 
reimbursed sofosbuvir/ledipasvir + ribavirin (89%, n=31) and elbasvir/grazoprevir + ribavirin 
(91%, n=32), and nearly three-quarters (74%, n=26) reimbursed sofosbuvir/velpatasvir + 
ribavirin. Some countries, namely Estonia, Latvia, Lithuania, Malta, and Romania, had 
comparatively fewer therapeutic options than other countries that reimbursed all HCV DAAs 
[Table 1].   
 
Nearly half of countries/jurisdictions (49%, n=17)required evidence of, at minimum, F2 
(METAVIR or equivalent). More specifically, 31% (n=11) of countries/jurisdictions required 
a minimum stage of F2; 17% (n=6) required ≥F3; 34% (n=12) had no fibrosis stage 
restrictions; 14% (n=5) had an additional requirement (e.g. point system that operates 
regardless of fibrosis stage). One country, Malta, had a minimum fibrosis stage of F4 [Figure 
1]. There were circumstances in which fibrosis stage was dependent on genotype. For 
example, Norway had no fibrosis stage restrictions for genotypes 1 and 4. The clinical 
recommendation in Norway was also age-dependent. Persons with genotype 3, <40 years, 
without cirrhosis, were offered peginterferon + ribavirin for 12 weeks as the first line of 
therapy.19, 20 In Austria and Switzerland, the minimum fibrosis stage was contingent on the 
HCV DAA therapy prescribed. For instance, sofosbuvir/ledipasvir + ribavirin and 
sofosbuvir/velpatasvir + ribavirin had a minimum fibrosis stage of F2 while 
elbasvir/grazoprevir + ribavirin had no fibrosis stage restrictions.21-24 
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Although 83% (n=29) of countries/jurisdictions had no listed drug or alcohol use restrictions, 
17% (n=6) required abstinence of drug and alcohol use prior to treatment (e.g. ≥6 months 
abstinence) [Figure 2]. This could include, but was not limited to, toxicological reports (e.g. 
urine drug screening) every three months to verify abstinence [see appendix p.2]. Hungary, in 
the case of injection drug use or alcohol use, required a psychiatric consult which supported 
the capability and compliance for treatment. In Romania, persons with HIV-HCV co-infection 
had to have a negative drug test to receive reimbursed therapy; this restriction did not seem to 
apply to persons with HCV monoinfection. In two countries, Liechtenstein and Switzerland, 
people who inject drugs (PWID) were prioritised for treatment uptake with no fibrosis stage 
restriction for PWID specifically. In countries in which there were no written guideline 
regarding substance use, study authors of each respective country emphasised that whether 
persons were eligible for treatment was ultimately up to physician discretion.  
 
Almost all countries/jurisdictions in Europe (94%; n=33) required a specialist, most often a 
gastroenterologist, hepatologist, internal medicine specialist, or infectious disease specialist 
to prescribe HCV DAAs [Figure 3]. England did allow prescribing by a general practitioner 
although specialist input from a local multi-disciplinary committee was required. Operational 
Delivery Networks, established by the National Health Service, England, are committees that 
oversee patient care and for HCV treatment. These specific networks determine who can 
prescribe HCV DAAs and also, prioritise patients for therapy. In Germany, all general 
practitioners can prescribe reimbursed HCV DAAs. Certain countries, e.g. France, did allow 
general practitioners trained in HCV care to monitor patients following initiation of HCV 
therapy. However, France still required a specialist to prescribe the DAA therapy. Some 
countries provided a list of specialist prescribers or alternatively, a list of specialist centres – 
e.g. Austria, Czech Republic, Slovakia, and Slovenia – which patients needed to attend to 
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receive a specialist prescription. Thus, not all specialists were in a position to prescribe HCV 
DAAs. 
 
Lastly, the majority of European countries/jurisdictions (97%, n=34) had no additional 
restrictions for HIV-HCV co-infected persons. Among countries that had minimum fibrosis 
stage restrictions for HCV monoinfected persons, 26% (n=9) of these countries had no 
fibrosis stage restrictions for HIV-HCV co-infected persons, and hence, HIV-HCV co-
infected persons were prioritised for treatment [Figure 4]. Specifically, in Belgium, Croatia, 
Czech Republic, Greece, Liechtenstein, Malta, Slovakia, Slovenia, and Switzerland, HIV-
HCV co-infected persons were offered HCV treatment regardless of fibrosis stage. In 
Romania, HIV-HCV co-infected persons needed to provide evidence of a negative drug test. 
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DISCUSSION 
This study demonstrated some similarities concerning DAA therapy access and 
reimbursement restrictions in Europe. Restrictions based on specialist prescribing were almost 
universal with 97% (n=33) of countries requiring a specialist to prescribe DAA therapy. 
Disease-based restrictions were common with nearly half of countries/jurisdictions (49%, 
n=17) restricting DAA therapy to persons with significant liver disease (≥F2). Further, nearly 
one-fifth of countries (17%, n=6) required patient abstinence from drug and/or alcohol use to 
qualify for reimbursed therapies. These restrictions are not in agreement with the 2016 
European Association for the Study of Liver (EASL) Recommendations on Treatment of 
Hepatitis C, which state that all patients without contraindications to therapy should be 
offered treatment.12 Additionally, in order to meet WHO targets of eliminating viral hepatitis 
as a major public health threat by 2030, these restrictions will need to be minimised.18  
 
To our knowledge, this is the first study to review HCV DAA reimbursement restrictions in 
Europe. This study is novel and its primary findings have major potential to influence clinical 
practice and policy. Similar studies on DAA restrictions have been used in legal and advocacy 
efforts to remove (or reduce) DAA reimbursement restrictions in Canada and US.8-10 The 
follow-up US reimbursement study provided evidence of states lessening (not adding) 
reimbursement restrictions over a mere two year period.8, 10 This further highlights the 
importance of conducting this Europe study to provide a baseline from which to compare 
DAA access in the upcoming years. A follow-up study on DAA access and restrictions in 
Europe would be beneficial. There were some limitations in the present study. Given that 
there was no systematic repository or standardized system for the collation of reimbursement 
restriction information, we relied on an extensive selection of documents as well as ongoing 
consultation with study authors to verify data accuracy. This study was limited to written 
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restrictions and prescribing practices by clinicians might differ from reimbursement criteria. 
For instance, among countries that have no listed drug use restriction, PWID may be much 
less likely to be offered DAA therapy. Further, if additional restrictions were reviewed, 
findings might have revealed even greater reimbursement discrepancies across 
countries/jurisdictions. In Belgium, for example, an elastography test and biomarker score 
were required to assess fibrosis stage (or alternatively, a liver biopsy).25 Similarly, countries 
may also differ on policies concerning retreatment. The present study also did not review 
intra-country variability. Persons who reside in rural-based areas or do not have private health 
insurance plans may encounter greater obstacles to reimbursed therapies. Such topics warrant 
further study. Research on heterogeneity in healthcare systems in Europe, specifically, how 
medication coverage (with varying deductible and/or co-pay arrangements) impacts treatment 
access at the patient level is also needed. With respect to reimbursement restrictions, we did 
not specifically look at the distinction between access and choice. In some countries, the 
available regimens might have been limited on the basis of restrictions put in place by the 
payer, which may have limited the selection of DAA therapies that physicians could choose to 
prescribe. Lastly, timeliness of data was a limitation in this study. While efforts were made to 
include the most current information, online information and documentation concerning DAA 
availability and reimbursement restrictions were frequently changing as therapies became 
approved and governments negotiated new agreements with pharmaceutical companies. 
Government ministries were not contacted to verify information, which is a noted study 
limitation. Nevertheless, this study provides an accurate assessment of reimbursement 
restrictions in Europe as of August 1, 2017.      
 
The considerable heterogeneity in DAA availability and reimbursement restrictions observed 
in Europe is consistent with previous studies evaluating regional differences in reimbursement 
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in Canada9 and the US.8, 10 Of note, 97% (n=34) of countries/jurisdictions in Europe required 
a specialist to prescribe DAAs compared to up to 42% of provinces/territories in Canada9 and 
67% of US states.10 Even in European countries/jurisdictions where primary care providers 
can prescribe, restrictions are in place through managed care networks (e.g. England) or 
alternatively, physicians are concerned with medical liability claims (e.g. Germany). In 
Australia, all medical providers (including primary care and drug/alcohol clinicians) are 
authorized to prescribe DAA therapy. Less experienced prescribers, however, are required to 
consult a gastroenterologist/hepatologist or infectious disease specialist in relation to 
appropriateness of DAA treatment. Under this system, an increasing proportion of DAA 
prescriptions are completed by primary care and non-specialist providers.26 Several factors are 
likely to influence current and future prescriber patterns including involvement of non-
specialists. Countries with more concentrated geography (less rural/remote regions), well 
developed specialist treatment centers with extensive referral pathways, and lower proportions 
of highly marginalized patients, may not require significant involvement of non-specialists. 
On the other hand, countries that expand to include non-specialists can be encouraged by 
evidence which demonstrates that HCV treatment outcomes by primary care providers and 
specialists are comparable.27, 28  
 
The WHO viral hepatitis strategy states that everyone living with viral hepatitis should have 
access to safe, affordable, and effective care.18 However, nearly half of European countries 
(49%, n=17) have restricted DAA reimbursement to persons with advanced liver disease 
(≥F2), which is also inconsistent with the 2016 EASL Recommendations on Treatment of 
Hepatitis C.12 Limiting DAA access to patients with more advanced liver disease (and other 
criteria such as genotype and age as seen in Norway) is a form of prioritisation in the context 
of high DAA drug pricing related to concerns regarding potential health budget impact, and 
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presumably, an interim strategy while awaiting development of further treatment 
infrastructure and declines in DAA pricing. Removal of liver disease stage restrictions is 
likely to occur in many countries in the near future as has happened recently in France. 
Successful treatment of HCV infection reduces progression of liver disease29 and lowers all-
cause mortality in people with advanced liver disease.30 Treatment of those with the greatest 
risk of transmission (e.g. PWID) also helps to prevent onward HCV transmission.31 As such, 
broadened access to DAA therapy will yield both individual and public health benefits.  
 
Seventeen percent (n=6) of European countries restricted access to DAA therapy among 
people with recent drug and/or alcohol use. Perceptions about poor adherence from ongoing 
substance use and risk of reinfection due to substance relapse are reasons often put forward to 
withhold HCV therapy from PWID.32, 33 A study of HCV practitioners in the DAA era (72% 
were gastroenterology and hepatology specialists) found that only 15% were willing to treat 
people who were actively injecting drugs.32 Promising data have demonstrated excellent 
adherence and response to DAA HCV therapy among people with recent drug use,34-39 people 
receiving opioid substitution therapy,40-48 and persons with recent injecting drug use.49-51 
Rates of reinfection among PWID are also relatively low.52, 53 In light of this evidence, there 
has been some debate as to the ethical justification for withholding therapy from people with 
ongoing drug/alcohol use.54  
 
This study has several key implications for clinicians and policy-makers. European countries 
should work towards removing restrictions that prevent primary care and drug/alcohol 
providers from prescribing DAA therapies. The 2016 EASL Recommendations on Treatment 
of Hepatitis C provide the guidance to ensure appropriate HCV management by medical 
providers.12 Mobilising specialists to mentor/train primary care and drug/alcohol providers, 
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simplifying pathways for the referral of people with advanced liver disease (e.g. APRI >1) to 
specialists, and providing HCV education and training for nurses, primary care providers, and 
drug/alcohol providers would all help to enable DAA access. The upcoming availability of 
pan-genotypic DAA therapies will also facilitate prescribing by primary care and drug/alcohol 
providers.   
 
While there is no ‘one size fits all’ strategy for the widespread implementation of HCV 
DAAs, a massive scale-up of testing, linkage to care, and treatment, particularly among high-
risk groups, will be required to reduce HCV incidence, HCV prevalence, and HCV-related 
morbidity and mortality.5, 17, 55, 56 Future efforts are needed to ensure appropriate monitoring 
and evaluation of country-level responses to HCV infection (which could then be added to 
national strategies and action plans) as well as the impact of DAA treatment uptake on HCV-
related morbidity and mortality.18, 57-59 Updated epidemiological data on the morbidity and 
mortality of HCV-related burden14, 60 would likely further strengthen national-level policy 
support for broadened HCV DAA access.  
 
DAA reimbursement restrictions throughout Europe are undoubtedly linked to the list price 
of DAA regimens. As a result, current reimbursement restrictions exist in most European 
countries related to prioritisation. The details of DAA prices (or discounts to list prices) are 
often not readily available, but there are considerable between-country differences in the 
discounts to list prices across Europe. Broad DAA access requires negotiations to lower DAA 
prices (or discounts to list prices) to facilitate removal of restrictions. Greater transparency in 
regard to these negotiations and outcomes is important for the broader strategic development 
towards ‘‘access for all”. The WHO mortality and incidence elimination targets are 
achievable and cost-effective61 in many countries but will require the collective efforts of 
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researchers, healthcare providers, policy-makers, the affected community, and the 
pharmaceutical industry to succeed.
 21 
 
Contributors  
Jason Grebely, Alison D. Marshall, Jeffrey V. Lazarus, Evan B. Cunningham, and Stine 
Nielsen contributed to study conception and design. A study concept sheet was circulated to 
all authors who provided comment on the study design. All authors contributed to data 
acquisition. Alison D. Marshall, Evan B. Cunningham, and Stine Nielsen contacted each 
study author from the country of interest to facilitate document access. Document searches 
were also conducted independently by Alison D. Marshall, Evan B. Cunningham, and Stine 
Nielsen to further corroborate search findings. Alison D. Marshall and Evan B. Cunningham 
categorized the outcome criteria of ~15 European countries/jurisdictions each and 
independently cross-checked each other’s categorization against the documentation.  Alison 
D. Marshall, Jason Grebely, Gregory J. Dore, Evan B. Cunningham, and Jeffrey V. Lazarus 
contributed to the drafting of the manuscript. All authors revised the manuscript.  
 
Declaration of interests   
Alessio Aghemo has received a research grant from Gilead Sciences, is on the advisory board 
for Janssen, Merck Sharp & Dohme, Bristol-Myers Squibb, Gilead Sciences, AbbVie, and has 
received personal fees from Janssen, Merck Sharp & Dohme, Bristol-Myers Squibb, Gilead 
Sciences, and AbbVie, outside the submitted work. Philip Bruggmann has received grants and 
personal fees from AbbVie, grants and personal fees from Merck Sharp & Dohme, grants and 
personal fees from Gilead, and grants and personal fees from Bristol-Myers Squibb, outside 
the submitted work. Olav Dalgard has received grants from Gilead Sciences, grants and 
personal fees from AbbVie, grants and personal fees from Merck Sharp & Dohme, outside the 
submitted work. Carole Seguin-Devaux has received grants from Gilead Sciences, outside the 
submitted work. Gregory J. Dore has received grants from AbbVie, Merck, Bristol-Myers 
Squibb, Janssen, and Roche, and personal fees from Gilead Sciences, AbbVie, Merck, Bristol-
 22 
 
Myers Squibb, Janssen, Roche, GlaxoSmithKline, and Abbott Diagnostics, and non-financial 
support from Gilead Sciences, AbbVie, Merck, Bristol-Myers Squibb, and Roche, outside the 
submitted work. Robert Flisiak has received grants and personal fees from AbbVie, grants and 
personal fees from Gilead Sciences, grants and personal fees from Merck, grants and personal 
fees from Roche, and personal fees from Janssen, outside the submitted work. Graham Foster 
has received grants and personal fees from Merck, grants and personal fees from Gilead 
Sciences, and grants and personal fees from AbbVie, during the conduct of the study, and is 
the National Clinical Lead for Hepatitis C in England. Jason Grebely has received grants from 
AbbVie, grants from Bristol-Myers Squibb, grants and personal fees from Gilead Sciences, 
grants and personal fees from Merck, and grants from Cepheid, outside the submitted work. 
Liana Gheorghe has received personal frees from AbbVie, Bristol-Myers Squibb, Gilead 
Sciences, and Merck Sharp & Dohme, and is part of the consulting/advisory board for Merck 
Sharp & Dohme, AbbVie and Gilead Sciences.  David Goldberg has received personal fees 
(honoraria) from Gilead Sciences, AbbVie, and Merck for non-product related lectures, 
outside the submitted work. Matthew Hickman has received personal fees from Merck Sharp 
& Dohme, AbbVie, and Gilead Sciences, outside the submitted work. Ligita Jancorienė has 
received personal fees and non-financial support (consulting fees, honorarium for lectures and 
payment for conducting clinical studies) from Merck Sharp & Dohme and AbbVie, outside 
the submitted work. Peter Jarcuska has received personal fees and non-financial support from 
AbbVie, personal fees and non-financial support from Gilead Sciences, and personal fees 
from Merck Sharp & Dohme, outside the submitted work. Martin Kåberg has received grants 
and personal fees from Gilead Sciences, personal fees from AbbVie, and personal fees from 
Merck Sharp & Dohme, outside the submitted work. Jeffrey V. Lazarus has received research 
grants and personal fees from AbbVie, Gilead Sciences, and Merck Sharp & Dohme, outside 
the submitted work. Michael Makara has been an investigator in clinical trials for Novartis, 
 23 
 
Bristol-Myers Squibb, Janssen-Cilag, AbbVie, Roche, Boehringer-Ingelheim, Merck Sharp & 
Dohme, and Regulus, and has received personal fees from Janssen-Cilag, AbbVie, Roche, 
Boehringer-Ingelheim, Merck Sharp and Dohme, and Gilead Sciences, outside the submitted 
work. Rui Tato Marinho has received personal fees and advisory board/speaker fees from 
AbbVie, personal fees and advisory board/speaker fees from Merck Sharp & Dohme, and 
personal fees and advisory board/speaker fees from Gilead Sciences.Sigurður Ólafsson has 
received personal fees from Merck Sharp & Dohme, outside the submitted work. Carlos 
Roncero has received speaker fees from Janssen-Cilag, Ferrer-Brainfarma, Pfizer, Reckitt-
Benckiser/Indivior, Lundbeck, Otsuka, Servier, Lilly, GSK, Astra, Sanofi, and Excelsis, 
received financial compensation for participation as a member of Janseen-Cilag, Indivior, 
Gilead Sciences, Merck Sharp & Dohme, and Munidipharma Board, carried out grants funded 
by Reckitt-Benckisert/Indivior, and Gilead Sciences, outside the submitted work. Anne 
Øvrehus has received personal fees and other (travel, speaker fee and consultancy) from 
AbbVie, grants, personal fees and other (travel and consultancy) from Gilead Sciences, 
personal fees from Bristol-Myers Squibb, and other (travel) from Merck Sharp & Dohme, 
outside the submitted work. James Pocock has received non-financial support from Gilead 
Sciences and non-financial support from AbbVie, outside the submitted work. Marieta 
Simonova has received speaker fees from AbbVie, Gilead Sciences, and Merck, and has been 
an advisor for AbbVie, Gilead Sciences, and Merck, outside the submitted work. Jan Sperl 
has received grants and personal fees from AbbVie, personal fees from Merck, personal fees 
from Gilead Sciences, personal fees from Bristol-Myers Squibb, and personal fees from 
Herbacos Recordati, outside the submitted work. Geert Robaeys has received research grants 
from Merck Sharp & Dohme, AbbVie, Janssen Pharmaceuticals, and has acted as a 
consultant/advisor for Gilead Sciences, AbbVie, Merck Sharp & Dohme, and Bristol-Myers 
Squibb. Ieva Tolmane has received honoraria for lectures from Merck Sharp & Dohme, and 
 24 
 
AbbVie. Marc van der Valk has received personal fees from AbbVie, personal fees from 
Bristol-Myers Squibb, grants and personal fees from Gilead Sciences, personal fees from 
Johnson & Johnson, grants, personal fees, and non-financial support from Merck Sharp & 
Dohme, and personal fees from ViiV, outside the submitted work. Adriana Vince has received 
personal fees and non-financial support from Gilead Sciences, personal fees from Merck 
Sharp & Dohme, and personal fees from AbbVie during the conduct of this study.  
 
Acknowledgements 
Study authors would like to thank the following persons for their assistance with retrieval of 
documentation and/or interpretation of documentation: Håvard Midgard (Department of 
Infectious Diseases, Akershus University Hospital, Norway; Institute for Clinical Medicine, 
University of Oslo, Norway; Department of Gastroenterology, Oslo University Hospital, 
Norway), Ecaterina Filep (The Kirby Institute, UNSW Sydney, Australia), Gerard Estivill 
Mercade (The Kirby Institute, UNSW Sydney, Australia), Marcel Schulz (The Kirby 
Institute, UNSW Sydney, Australia), Rainer Puhr (The Kirby Institute, UNSW Sydney, 
Australia), Petros Katsioloudes (Ministry of Health, Cyprus), Ioannis Demetriades (Grigorios 
Clinic, Larnaca General Hospital, Cyprus), the All Wales Therapeutics and Toxicology 
Centre (Penarth, UK), and the NIHR Health Protection Research Unit (HPRU) in Evaluation 
of Interventions (University of Bristol, UK).  
 
The Kirby Institute is funded by the Australian Government Department of Health. The views 
expressed in this publication do not necessarily represent the position of the Australian 
Government. ADM holds a University International Postgraduate Award from UNSW Sydney 
and is also supported by the CanHepC Trainee Program (Canada). EBC is supported by the 
CanHepC Trainee Program (Canada). JG is supported by a National Health and Medical 
 25 
 
Research Council Career Development Fellowship. GJD is supported by a National Health 
and Medical Research Council Practitioner Research Fellowship.   
 26 
 
REFERENCES 
1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution 
of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol 
Hepatol. 2017;2(3):161-76. 
2. World Health Organization. Global Hepatitis Report 2017. Geneva World Health 
Organization 2017; License: CC BY-NC-SA 3.0 IG0. 
3. Global, regional, and national age–sex specific all-cause and cause-specific mortality 
for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of 
Disease Study 2013. The Lancet. 2015;385(9963):117-71. 
4. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of 
"perfectovir". Clin Infect Dis. 2015;60(12):1829-36. 
5. Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide - 
filling the gaps. J Viral Hepat. 2015;22 Suppl 1:1-5. 
6. Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, et al. 
Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2. J 
Viral Hepat. 2015;22 Suppl 1:46-73. 
7. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. 
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of 
Liver and Non-Liver Complications. Gastroenterology. 2017;152(1):142-56 e2. 
8. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for 
Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus 
Infection in the United States. Ann Intern Med. 2015;163(3):215-23. 
9. Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, et al. Restrictions 
for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in 
Canada: a descriptive study. CMAJ open. 2016;4(4):E605-E14. 
10. Ooka K, Connolly JJ, Lim JK. Medicaid Reimbursement for Oral Direct Antiviral 
Agents for the Treatment of Chronic Hepatitis C. Am J Gastroenterol. 
2017;112(6):828-32. 
11. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA 
recommendations for testing, managing, and treating adults infected with hepatitis C 
virus. Hepatology. 2015;62(3):932-54. 
12. EASL. EASL Recommendations on treatment of hepatitis C 2016. J Hepatol. 
2017;66(1):153-94. 
13. World Health Organization. Guidelines for the screening, care and treatment of 
persons with chronic hepatitis C infection 2016. 1-138]. Available from: Available: 
http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/ (accessed 
2017 January 12). 
14. Razavi H, Robbins S, Zeuzem S, Negro F, Buti M, Duberg A-S, et al. Hepatitis C 
virus prevalence and level of intervention required to achieve the WHO targets for 
elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol 
Hepatol. 2017;2(5):325-36. 
15. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV 
infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-62. 
16. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, et al. The 
present and future disease burden of hepatitis C virus (HCV) infections with today's 
treatment paradigm - volume 2. J Viral Hepat. 2015;22 Suppl 1:26-45. 
17. Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, et 
al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. 
J Viral Hepat. 2015;22 Suppl 1:6-25. 
 27 
 
18. World Health Organization. Global health sector strategy on viral hepatitis 2016-
2021. Towards ending viral hepatitis. June 2016. 1-56]. Available from: 
http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/  (accessed 2017 May 
21). 
19. Sykehusinnkjøp HF. HCV guidelines for the Norwegian Health Authorities. February 
8, 2017. . Available from: Available: http://sykehusinnkjop.no/wp-
content/uploads/2017/02/LIS-HCV-anbefalinger-2017-leverand%C3%B8rer.pdf 
(accessed 2017 May 10). 
20. Norwegian Medical Association. Faglig Veileder for Utredning og Behandling av 
Hepatitt C hos voksne. March 2017. Clinical Recommendations for Hepatitis C 
Treatment in Norway. Contact Ministry of Health Norway for more information 
(accessed 2017 May 5). 
21. Schweizerische Eidgenossenschaft. Spezialitätenliste (SL), Index der SL-
Verzeichnisse. 2017. Online Drug Formulary. Available from: Available: 
http://www.spezialitaetenliste.ch/ (accessed 23 Feburary 2017). 
22. Chandrasekhar A. Swiss Hepatitis C Sufferers to get Full Access to Expensive Drug. 
June 26, 2017. Available from: Available: https://www.swissinfo.ch/eng/zepatier-
_swiss-hepatitis-c-sufferers-to-get-full-access-to-expensive-drug/43288924 (accessed 
2017 June 27). 
23. Erstattungskodex – EKO. Im Blickpunkt-Tipps. NEU im EKO. Sammelband Mai, 
Juni und Juli 2017. Available from: Available: 
http://www.bgkk.at/cdscontent/load?contentid=10008.642874&version=1499412330 
(accessed 2017 August 1). 
24. Schweizerische Eidgenossenschaft. Drugs Against Hepatitis C: Strong Price 
Reduction and Extended Remuneration. 2017. Available from: Available: 
www.bag.admin.ch/bag/de/home/aktuell/news/news-26-06-2017.html (accessed 2017 
June 27). 
25. Belgian Association for the Study of the Liver. Belgian HCV Therapy Guidance 
Update January 2017. Available from: Available: 
http://www.basl.be/sites/default/files/Belgian%20HCV%20therapy%20guidance%20
update%20january%202017_final_25012017.pdf (accessed 2017 May 19). 
26. The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia (Issue 3) 
Sydney, Australia [updated February 2017]. Available from: Available: 
https://kirby.unsw.edu.au/sites/default/files/kirby/report/Monitoring-hep-C-treatment-
uptake-in-Australia_Iss6-FEB17.pdf (accessed 2017 March 17). 
27. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of 
treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 
2011;364(23):2199-207. 
28. Kattakuzhy SM, Gross C, Teferi G, Jenkins V, Emmanuel B, Masur H, et al., editors. 
High Efficacy of HCV Treatment by Primary Care Providers: The ASCEND Study. 
Conference on Retroviruses and Opportunistic Infections; February 22–25, 2016 
Boston, MA, USA. 
29. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin 
Liver Dis. 2011;31(4):331-9. 
30. van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, et al. 
Life expectancy in patients with chronic HCV infection and cirrhosis compared with a 
general population. JAMA. 2014;312(18):1927-8. 
31. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. 
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling 
 28 
 
treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598-
609. 
32. Asher AK, Portillo CJ, Cooper BA, Dawson-Rose C, Vlahov D, Page KA. Clinicians' 
views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens 
for people who inject drugs. Subst Use Misuse. 2016;51(9):1218-23. 
33. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C 
virus (HCV) treatment among individuals with HCV/HIV coinfection: action required 
at the system, provider, and patient levels. J Infect Dis. 2013;207 Suppl 1:S19-25. 
34. Norton BL, Fleming J, Steinman M, Yu K, Deluca J, Cunningham CO, et al., editors. 
High HCV Cure Rates for Drug Users Treated with DAAs at an Urban Primary Care 
Clinic. Conference on Retroviruses and Opportunistic Infections; Feb 22-24 Boston, 
MA, USA. 
35. Conway B, Raycraft T, Bhutani Y, Kiani G, Shahi R, Singh A, et al. Efficacy of all-
oral HCV therapy in people who inject drugs (Abstract #1992). Hepatology. 
2016;64(S1):990A. 
36. Sulkowski M, Ward K, Falade-Nwulia O, Moon J, Sutcliffe C, Brinkley S, et al. 
Randomized controlled trial of cash incentives or peer mentors to improve HCV 
linkage and treatment among HIV/HCV coinfected persons who inject drugs: the 
CHAMPS Study. J Hepatol. 2017;66:S719. 
37. Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J, et al. Understanding 
Real-World Adherence in the Directly Acting Antiviral Era: a prospective evaluation 
of adherence amongst people with a history of drug use at a community-based 
program in Toronto, Canada. Int J Drug Policy. 2017;In Press. 
38. Morris L, Smirnov A, Kvassay A, Leslie E, Kavanagh R, Alexander N, et al. Initial 
outcomes of integrated community-based hepatitis C treatment for people who inject 
drugs: Findings from the Queensland Injectors' Health Network. Int J Drug Policy. 
2017. 
39. Read P, Lothian R, Chronister K, Gilliver R, Kearley J, Dore GJ, et al. Delivering 
direct acting antiviral therapy for hepatitis C to highly marginalised and current drug 
injecting populations in a targeted primary health care setting. Int J Drug Policy. 
2017. 
40. Puoti M, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, et al. ABT-
450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-
infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of 
Efficacy and Safety in Phase 2 and Phase 3 Trials. Hepatology. 2014;60:1135a-6a. 
41. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment 
of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 
2014;370(17):1594-603. 
42. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-
Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients 
with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann 
Intern Med. 2015;163(1):1-13. 
43. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, et al. Efficacy and safety 
of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving 
opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis. 2016. 
44. Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, et al. Efficacy and 
Safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic 
HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 
ION trials. Clin Infect Dis. 2016. 
 29 
 
45. Grebely J, Puoti M, Wedemeyer H, Cooper CS, Sulkowski MS, Foster GF, et al. 
Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without 
ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled 
analysis across 12 clinical trials. J Hepatol. 2017;66:S514. 
46. Grebely J, Jacobson IM, Kayali Z, Verna EC, Shiffman ML, Hyland RH, et al. 
Sof/vel/vox for 8 or 12 weeks is well tolerated and results in high SVR12 rates in 
patients receiving opioid substitution therapy. J Hepatol. 2017;66:S513. 
47. Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, et al. 
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected 
patients on methadone or buprenorphine. J Hepatol. 2015;63(2):364-9. 
48. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir-
grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist 
therapy: a randomized trial. Ann Intern Med. 2016;165(9):625-34. 
49. Bouscaillou J, Kikvidze T, Butsashvili M, Labartkava K, Inaridze I, Etienne A, et al. 
Effectiveness of DAA-based treatment of HCV in active people who inject drugs 
living in middle income countries (MIC): the results of a prospective cohort study in 
Tbilisi, Georgia. J Hepatol. 2017;66:S409. 
50. Boglione L, Mornese Pinna S, De Nicolo A, Cusato J, Cariti G, Di Perri G, et al. 
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting 
drug users: A prospective study. J Viral Hepat. 2017. 
51. Grebely J, Dalgard O, Conway B, Cunningham E, Bruggmann P, Hajarizadeh B, et al. 
Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus 
infection and recent injecting drug use: the SIMPLIFY study. J Hepatol. 
2017;66:S513. 
52. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. 
Elbasvir/Grazoprevir to Treat HCV Infection in Persons Receiving Opioid Agonist 
Therapy: A Randomized Controlled Trial (C-EDGE CO-STAR). Annals of internal 
medicine. 2016;In Press. 
53. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment 
of hepatitis C virus infection among people who are actively injecting drugs: a 
systematic review and meta-analysis. Clin Infect Dis. 2013;57 Suppl 2:S80-9. 
54. Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, et al. Excluding 
people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, 
given the available data? J Hepatol. 2015;63(4):779-82. 
55. Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, et al. Historical 
epidemiology of hepatitis C virus (HCV) in select countries - volume 3. J Viral 
Hepat. 2015;22 Suppl 4:4-20. 
56. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval 
F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J 
Viral Hepat. 2014;21 Suppl 1:5-33. 
57. World Health Organization. Manual for the development and assessment of national 
viral hepatitis plans. September 2015. . 1-62.]. Available from: Available: 
www.who.int/hepatitis/publications/manual-hep-plan/en/ (accessed 2017 May 19)    
58. European Liver Patients Association. The 2016 Hep-Core Report. Monitoring the 
implementation of hepatitis B and C policy recommendations in Europe. March 2017. 
1-158]. Available from: http://www.elpa.eu/sites/default/files/project-documents/Hep-
CORE_full_report_21Mar2017_errata_Final.pdf (accessed 2017 May 30). 
59. World Health Organization. Regional committee for Europe 66th session. Action plan 
for the health sector response to viral hepatitis in the WHO European Region. 
Copenhagen, Denmark, 12-15 September 2016, . Available from: Available: 
 30 
 
http://www.euro.who.int/en/about-us/governance/regional-committee-for-
europe/66th-session/documentation/working-documents/eurrc6610-action-plan-for-
the-health-sector-response-to-viral-hepatitis-in-the-who-european-region (accessed 
2017 June 23). 
60. Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-
related burden of disease in Europe: a systematic assessment of incidence, prevalence, 
morbidity, and mortality. BMC Public Health. 2009;9:34. 
61. Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME. Treatment scale-up to 
achieve global HCV incidence and mortality elimination targets: a cost-effectiveness 
model. Gut. 2016. 
 31 
 
 
 32 
 
Table 1.  Availability of reimbursed interferon-free DAAs for HCV infection in Europe 
 
 
HCV DAA Therapy 
 
SO
F + R
BV
 
 
SO
F/LED
 ±
 R
BV
 
 
SO
F/V
EL
 ±
 
 R
BV
 
PrO
D
 ±
 R
BV
 
EBR
-G
ZR
 ±
 
 R
BV
 
 
SO
F + D
C
V
 ±
 
 R
BV
 
Austria  YES YES YES YES YESµ YES  
Belgium YES YES YES  YES  YES  YES  
Bulgaria  YES YES NO YES YES NO 
Croatia YES YES YES YES YES NO 
Cyprus YES YES YES YES YES NO 
Czech Republic  YES YES YES YES YES YES 
Denmark  YES YES YES YES YES YES 
England YES YES YES YES YES  YESβ  
Estonia  NO NO NO YES¶ YES¶ NO 
Finland YES YES YES NO YES NO 
France  YES YES YES YES YES YES 
Germany YES YES YES YES YES  YES 
Greece  YES YES YES YES YES YES 
Hungary NO YES NO YES NO NO 
Iceland  YES YES YES YES YES YES 
Ireland  NO YES YES YES YES YES 
Italy YES YES YES YES YES YES 
Latvia  NO NO NO YESβ  YESβ NO 
Liechtenstein YES YES YES YES YESµ YES 
Lithuania NO NO NO YES YESβ NO 
Luxembourg  YES YES YES YES YES YES 
Malta  YES YES NO NO NO NO 
Netherlands  YES YES YES YES YES YES 
N. Ireland YES YES  YES  YES  YES YES  
Norway YES YES YES YES YES YES 
Poland YES YES NO YES YES NO 
Portugal  YES  YES  YES YES  YES YES 
Romania  NO NO NO YES NO NO 
Scotland YES YES YES  YES YES YES† 
Slovakia  YES YES NO YES YES NO 
Slovenia YES YES YES YES YES NO 
Spain YES YES YES YES  YES YES 
Sweden  YES* YES* YES YES  YES YES* 
Switzerland  YES  YES YES  YESµ  YESµ  YES  
Wales  YES  YES YES  YES YES YES† 
βRestricted to fibrosis stage of ≥F3  
*Special consideration is required  
‡Need to be GT3, treatment naïve with ≥F3 
 µThere are no fibrosis stage restrictions for GT1 and GT4 
 ¶Reimbursed regardless of fibrosis stage in patients with cryoglobulinemia and post orthotopic transplantation 
.
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Figure 1. Minimum fibrosis stage required for reimbursement of interferon-free DAAs for treatment 
naïve patients with HCV infection in Europe 
 
 
*Please note: This figure was uploaded separately
a
 
Fibrosis stage restrictions based on HCV genotype 
b 
Fibrosis stage is included in a point system for prioritisation of DAA therapy 
c
Fibrosis stage restrictions based on HCV genotype and IL28B polymorphism 
d Fibrosis stage restrictions based on HCV therapy 
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Figure 2. Drug and alcohol restrictions for reimbursement of interferon-free DAAs for patients with HCV 
infection in Europe  
 
 
*Please note: This figure was uploaded separately
a
 
Persons with HIV-HCV co-infection had to have a negative drug test in order to receive reimbursed therapy 
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Figure 3. Prescriber-type restrictions for reimbursement of interferon-free DAAs for patients with HCV 
infection in Europe 
  
 
*Please note: This figure was uploaded separately
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Figure 4. HIV co-infection restrictions for reimbursement of interferon-free DAAs for patients with HCV 
infection in Europe 
 
 
*Please note: This figure was uploaded separately 
 
a
 
Persons with HIV-HCV co-infection had to have a negative drug test in order to receive reimbursed therapy 
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